Submitted first 2 in October, 3rd item in November
Post# of 148162
"And we're nearing the end of the analysis for those two remaining items. Thus far, we have not seen any systemic concerns with how leronlimab has been tolerated across the previous 22 trials, and we look forward to submitting these final two items very shortly with the FDA"
Draw your own conclusions...my money is on Jan'23 hold lift.